OncoMatch/Clinical Trials/NCT05974449
Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients
Is NCT05974449 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Vaginal Lactobacillus capsules for breast cancer female.
Treatment: Vaginal Lactobacillus capsules — This study is a prospective, randomized controlled, phase II clinical study with a planned enrolment of 60 patients. The study focuses on the efficacy and safety of Lactobacillus vaginalis capsules for the prevention and/or treatment of vulvovaginal symptoms in young breast cancer patients receiving ovarian protection during chemotherapy, in order to improve compliance and quality of life in breast cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Kidney function
serum creatinine < 1.5x uln
Liver function
ast and alt < 1.5x uln, alkaline phosphatase < 2.5x uln, total bilirubin < 1.5x uln
Cardiac function
lvef >= 50% on cardiac ultrasound
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05974449 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages